Final trial results confirm that CureVac’s mRNA vaccine is far less protective than others.

The German company’s vaccine had an overall efficacy of just 48 percent, but that rose to 53 percent among those between the ages of 18 and 60.

CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.

The results were a blow to hopes that the vaccine could help meet the world’s urgent need. “This is pretty devastating” for the company, one expert said.

CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial

A preliminary analysis showed that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.